nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—YES1—seminal vesicle—rectum cancer	0.00114	0.00226	CbGeAlD
Bosutinib—MAP4K1—vagina—rectum cancer	0.00113	0.00225	CbGeAlD
Bosutinib—MAP3K7—urethra—rectum cancer	0.00113	0.00224	CbGeAlD
Bosutinib—BTK—vagina—rectum cancer	0.00113	0.00224	CbGeAlD
Bosutinib—AXL—smooth muscle tissue—rectum cancer	0.00113	0.00224	CbGeAlD
Bosutinib—TAOK3—seminal vesicle—rectum cancer	0.00112	0.00223	CbGeAlD
Bosutinib—SIK1—mammalian vulva—rectum cancer	0.00112	0.00222	CbGeAlD
Bosutinib—IRAK4—mammalian vulva—rectum cancer	0.00112	0.00222	CbGeAlD
Bosutinib—TBK1—urethra—rectum cancer	0.00112	0.00222	CbGeAlD
Bosutinib—PTK2—urethra—rectum cancer	0.00112	0.00222	CbGeAlD
Bosutinib—EPHB4—epithelium—rectum cancer	0.00112	0.00222	CbGeAlD
Bosutinib—TLK1—lymph node—rectum cancer	0.00111	0.00221	CbGeAlD
Bosutinib—EPHA4—mammalian vulva—rectum cancer	0.00111	0.0022	CbGeAlD
Bosutinib—MAP4K4—female reproductive system—rectum cancer	0.0011	0.00219	CbGeAlD
Bosutinib—PRKCQ—lymph node—rectum cancer	0.0011	0.00218	CbGeAlD
Bosutinib—EPHA2—epithelium—rectum cancer	0.0011	0.00217	CbGeAlD
Bosutinib—MAP4K2—vagina—rectum cancer	0.00109	0.00217	CbGeAlD
Bosutinib—RPS6KB1—renal system—rectum cancer	0.00109	0.00217	CbGeAlD
Bosutinib—MAP2K2—mammalian vulva—rectum cancer	0.00109	0.00217	CbGeAlD
Bosutinib—ULK3—mammalian vulva—rectum cancer	0.00109	0.00217	CbGeAlD
Bosutinib—BCR—female reproductive system—rectum cancer	0.00109	0.00217	CbGeAlD
Bosutinib—MAP3K12—female reproductive system—rectum cancer	0.00109	0.00216	CbGeAlD
Bosutinib—ERBB4—vagina—rectum cancer	0.00108	0.00214	CbGeAlD
Bosutinib—STK3—vagina—rectum cancer	0.00108	0.00214	CbGeAlD
Bosutinib—MAP3K7—mammalian vulva—rectum cancer	0.00108	0.00214	CbGeAlD
Bosutinib—EPHB4—smooth muscle tissue—rectum cancer	0.00108	0.00214	CbGeAlD
Bosutinib—RPS6KB1—urethra—rectum cancer	0.00108	0.00214	CbGeAlD
Bosutinib—FGR—urethra—rectum cancer	0.00107	0.00212	CbGeAlD
Bosutinib—LCK—urethra—rectum cancer	0.00107	0.00212	CbGeAlD
Bosutinib—MAP2K1—female reproductive system—rectum cancer	0.00106	0.00211	CbGeAlD
Bosutinib—STK35—female reproductive system—rectum cancer	0.00106	0.00211	CbGeAlD
Bosutinib—AXL—urethra—rectum cancer	0.00106	0.00211	CbGeAlD
Bosutinib—TBK1—mammalian vulva—rectum cancer	0.00106	0.00211	CbGeAlD
Bosutinib—CSK—female reproductive system—rectum cancer	0.00106	0.0021	CbGeAlD
Bosutinib—FYN—smooth muscle tissue—rectum cancer	0.00105	0.00209	CbGeAlD
Bosutinib—CSNK1A1—female reproductive system—rectum cancer	0.00105	0.00209	CbGeAlD
Bosutinib—CLK1—female reproductive system—rectum cancer	0.00104	0.00207	CbGeAlD
Bosutinib—IRAK1—mammalian vulva—rectum cancer	0.00104	0.00207	CbGeAlD
Bosutinib—BMPR2—vagina—rectum cancer	0.00104	0.00206	CbGeAlD
Bosutinib—EPHB4—renal system—rectum cancer	0.00104	0.00206	CbGeAlD
Bosutinib—CLK3—lymph node—rectum cancer	0.00103	0.00205	CbGeAlD
Bosutinib—DSTYK—lymph node—rectum cancer	0.00103	0.00205	CbGeAlD
Bosutinib—BMX—lymph node—rectum cancer	0.00103	0.00205	CbGeAlD
Bosutinib—MAP4K5—smooth muscle tissue—rectum cancer	0.00103	0.00204	CbGeAlD
Bosutinib—STK36—vagina—rectum cancer	0.00103	0.00204	CbGeAlD
Bosutinib—EPHB3—vagina—rectum cancer	0.00103	0.00204	CbGeAlD
Bosutinib—CAMK2G—female reproductive system—rectum cancer	0.00102	0.00203	CbGeAlD
Bosutinib—BMP2K—female reproductive system—rectum cancer	0.00102	0.00203	CbGeAlD
Bosutinib—SLK—urethra—rectum cancer	0.00102	0.00203	CbGeAlD
Bosutinib—RPS6KB1—mammalian vulva—rectum cancer	0.00102	0.00203	CbGeAlD
Bosutinib—BLK—lymph node—rectum cancer	0.00102	0.00202	CbGeAlD
Bosutinib—LCK—mammalian vulva—rectum cancer	0.00102	0.00202	CbGeAlD
Bosutinib—FGR—mammalian vulva—rectum cancer	0.00102	0.00202	CbGeAlD
Bosutinib—EPHB4—urethra—rectum cancer	0.00102	0.00202	CbGeAlD
Bosutinib—MERTK—vagina—rectum cancer	0.00102	0.00202	CbGeAlD
Bosutinib—LRRK2—female reproductive system—rectum cancer	0.00102	0.00202	CbGeAlD
Bosutinib—FYN—renal system—rectum cancer	0.00101	0.00201	CbGeAlD
Bosutinib—AXL—mammalian vulva—rectum cancer	0.00101	0.00201	CbGeAlD
Bosutinib—PHKG1—lymph node—rectum cancer	0.00101	0.002	CbGeAlD
Bosutinib—CASK—lymph node—rectum cancer	0.00101	0.002	CbGeAlD
Bosutinib—MAP2K5—seminal vesicle—rectum cancer	0.001	0.002	CbGeAlD
Bosutinib—EPHA2—urethra—rectum cancer	0.000998	0.00198	CbGeAlD
Bosutinib—EIF2AK1—lymph node—rectum cancer	0.000997	0.00198	CbGeAlD
Bosutinib—MAP4K4—vagina—rectum cancer	0.000997	0.00198	CbGeAlD
Bosutinib—FYN—urethra—rectum cancer	0.000996	0.00198	CbGeAlD
Bosutinib—NUAK2—vagina—rectum cancer	0.00099	0.00197	CbGeAlD
Bosutinib—BCR—vagina—rectum cancer	0.00099	0.00197	CbGeAlD
Bosutinib—PTK2B—female reproductive system—rectum cancer	0.000989	0.00197	CbGeAlD
Bosutinib—MAP3K12—vagina—rectum cancer	0.000983	0.00195	CbGeAlD
Bosutinib—CSF1R—seminal vesicle—rectum cancer	0.000981	0.00195	CbGeAlD
Bosutinib—TXK—lymph node—rectum cancer	0.000976	0.00194	CbGeAlD
Bosutinib—SLK—mammalian vulva—rectum cancer	0.000975	0.00194	CbGeAlD
Bosutinib—CSNK1E—female reproductive system—rectum cancer	0.000973	0.00193	CbGeAlD
Bosutinib—MAP4K5—urethra—rectum cancer	0.000973	0.00193	CbGeAlD
Bosutinib—MAP3K3—urethra—rectum cancer	0.000973	0.00193	CbGeAlD
Bosutinib—EPHB4—mammalian vulva—rectum cancer	0.000968	0.00192	CbGeAlD
Bosutinib—FES—lymph node—rectum cancer	0.000966	0.00192	CbGeAlD
Bosutinib—VRK2—lymph node—rectum cancer	0.000966	0.00192	CbGeAlD
Bosutinib—STK35—vagina—rectum cancer	0.000963	0.00191	CbGeAlD
Bosutinib—SIK1—female reproductive system—rectum cancer	0.000958	0.0019	CbGeAlD
Bosutinib—CSK—vagina—rectum cancer	0.000956	0.0019	CbGeAlD
Bosutinib—YES1—smooth muscle tissue—rectum cancer	0.000951	0.00189	CbGeAlD
Bosutinib—CSNK1A1—vagina—rectum cancer	0.00095	0.00189	CbGeAlD
Bosutinib—EPHA2—mammalian vulva—rectum cancer	0.00095	0.00189	CbGeAlD
Bosutinib—SRC—epithelium—rectum cancer	0.000949	0.00188	CbGeAlD
Bosutinib—EPHA4—female reproductive system—rectum cancer	0.000949	0.00188	CbGeAlD
Bosutinib—FYN—mammalian vulva—rectum cancer	0.000948	0.00188	CbGeAlD
Bosutinib—TNIK—lymph node—rectum cancer	0.000948	0.00188	CbGeAlD
Bosutinib—SYK—lymph node—rectum cancer	0.000948	0.00188	CbGeAlD
Bosutinib—HCK—vagina—rectum cancer	0.000944	0.00187	CbGeAlD
Bosutinib—CLK1—vagina—rectum cancer	0.000944	0.00187	CbGeAlD
Bosutinib—ERBB3—female reproductive system—rectum cancer	0.000939	0.00187	CbGeAlD
Bosutinib—CDK2—lymph node—rectum cancer	0.000939	0.00186	CbGeAlD
Bosutinib—ABL2—vagina—rectum cancer	0.000938	0.00186	CbGeAlD
Bosutinib—ULK3—female reproductive system—rectum cancer	0.000937	0.00186	CbGeAlD
Bosutinib—MAP2K2—female reproductive system—rectum cancer	0.000937	0.00186	CbGeAlD
Bosutinib—MAP3K2—female reproductive system—rectum cancer	0.00093	0.00185	CbGeAlD
Bosutinib—STK26—lymph node—rectum cancer	0.00093	0.00185	CbGeAlD
Bosutinib—MAP4K5—mammalian vulva—rectum cancer	0.000927	0.00184	CbGeAlD
Bosutinib—MAP3K3—mammalian vulva—rectum cancer	0.000927	0.00184	CbGeAlD
Bosutinib—CAMK2G—vagina—rectum cancer	0.000927	0.00184	CbGeAlD
Bosutinib—BMP2K—vagina—rectum cancer	0.000927	0.00184	CbGeAlD
Bosutinib—LRRK2—vagina—rectum cancer	0.000918	0.00182	CbGeAlD
Bosutinib—YES1—renal system—rectum cancer	0.000915	0.00182	CbGeAlD
Bosutinib—SRC—smooth muscle tissue—rectum cancer	0.000915	0.00182	CbGeAlD
Bosutinib—TBK1—female reproductive system—rectum cancer	0.000911	0.00181	CbGeAlD
Bosutinib—PTK2—female reproductive system—rectum cancer	0.000911	0.00181	CbGeAlD
Bosutinib—STK10—renal system—rectum cancer	0.000907	0.0018	CbGeAlD
Bosutinib—TAOK3—renal system—rectum cancer	0.000903	0.00179	CbGeAlD
Bosutinib—YES1—urethra—rectum cancer	0.000899	0.00179	CbGeAlD
Bosutinib—CHEK2—lymph node—rectum cancer	0.000898	0.00178	CbGeAlD
Bosutinib—PTK2B—vagina—rectum cancer	0.000895	0.00178	CbGeAlD
Bosutinib—IRAK1—female reproductive system—rectum cancer	0.000893	0.00177	CbGeAlD
Bosutinib—WEE1—lymph node—rectum cancer	0.000891	0.00177	CbGeAlD
Bosutinib—DMPK—lymph node—rectum cancer	0.000891	0.00177	CbGeAlD
Bosutinib—TAOK3—urethra—rectum cancer	0.000887	0.00176	CbGeAlD
Bosutinib—CSNK1E—vagina—rectum cancer	0.00088	0.00175	CbGeAlD
Bosutinib—SRC—renal system—rectum cancer	0.00088	0.00175	CbGeAlD
Bosutinib—RPS6KB1—female reproductive system—rectum cancer	0.000876	0.00174	CbGeAlD
Bosutinib—FGR—female reproductive system—rectum cancer	0.000871	0.00173	CbGeAlD
Bosutinib—PDGFRB—seminal vesicle—rectum cancer	0.00087	0.00173	CbGeAlD
Bosutinib—AXL—female reproductive system—rectum cancer	0.000868	0.00172	CbGeAlD
Bosutinib—IRAK4—vagina—rectum cancer	0.000867	0.00172	CbGeAlD
Bosutinib—EPHA4—vagina—rectum cancer	0.000858	0.0017	CbGeAlD
Bosutinib—YES1—mammalian vulva—rectum cancer	0.000856	0.0017	CbGeAlD
Bosutinib—STK25—lymph node—rectum cancer	0.000851	0.00169	CbGeAlD
Bosutinib—STK10—mammalian vulva—rectum cancer	0.000848	0.00168	CbGeAlD
Bosutinib—ULK3—vagina—rectum cancer	0.000847	0.00168	CbGeAlD
Bosutinib—TAOK3—mammalian vulva—rectum cancer	0.000845	0.00168	CbGeAlD
Bosutinib—EPHA3—lymph node—rectum cancer	0.000845	0.00168	CbGeAlD
Bosutinib—MAP3K7—vagina—rectum cancer	0.000834	0.00166	CbGeAlD
Bosutinib—EPHB4—female reproductive system—rectum cancer	0.000829	0.00165	CbGeAlD
Bosutinib—PLK2—lymph node—rectum cancer	0.000827	0.00164	CbGeAlD
Bosutinib—TBK1—vagina—rectum cancer	0.000824	0.00164	CbGeAlD
Bosutinib—PTK2—vagina—rectum cancer	0.000824	0.00164	CbGeAlD
Bosutinib—SIK3—lymph node—rectum cancer	0.000822	0.00163	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—rectum cancer	0.000821	0.00163	CbGeAlD
Bosutinib—EPHA2—female reproductive system—rectum cancer	0.000813	0.00162	CbGeAlD
Bosutinib—FYN—female reproductive system—rectum cancer	0.000812	0.00161	CbGeAlD
Bosutinib—MAP2K5—urethra—rectum cancer	0.000796	0.00158	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—rectum cancer	0.000794	0.00158	CbGeAlD
Bosutinib—MAP3K3—female reproductive system—rectum cancer	0.000794	0.00158	CbGeAlD
Bosutinib—RPS6KB1—vagina—rectum cancer	0.000793	0.00157	CbGeAlD
Bosutinib—STK4—lymph node—rectum cancer	0.000791	0.00157	CbGeAlD
Bosutinib—FGR—vagina—rectum cancer	0.000788	0.00156	CbGeAlD
Bosutinib—LCK—vagina—rectum cancer	0.000788	0.00156	CbGeAlD
Bosutinib—AXL—vagina—rectum cancer	0.000785	0.00156	CbGeAlD
Bosutinib—CAMK1D—lymph node—rectum cancer	0.000781	0.00155	CbGeAlD
Bosutinib—CSF1R—urethra—rectum cancer	0.000776	0.00154	CbGeAlD
Bosutinib—ABL1—seminal vesicle—rectum cancer	0.000775	0.00154	CbGeAlD
Bosutinib—STK24—lymph node—rectum cancer	0.000772	0.00153	CbGeAlD
Bosutinib—MAP2K5—mammalian vulva—rectum cancer	0.000757	0.0015	CbGeAlD
Bosutinib—PDGFRB—epithelium—rectum cancer	0.000756	0.0015	CbGeAlD
Bosutinib—SLK—vagina—rectum cancer	0.000755	0.0015	CbGeAlD
Bosutinib—EPHB4—vagina—rectum cancer	0.00075	0.00149	CbGeAlD
Bosutinib—ALK—lymph node—rectum cancer	0.000747	0.00148	CbGeAlD
Bosutinib—FER—lymph node—rectum cancer	0.000747	0.00148	CbGeAlD
Bosutinib—CSF1R—mammalian vulva—rectum cancer	0.000739	0.00147	CbGeAlD
Bosutinib—EPHA2—vagina—rectum cancer	0.000736	0.00146	CbGeAlD
Bosutinib—FYN—vagina—rectum cancer	0.000734	0.00146	CbGeAlD
Bosutinib—YES1—female reproductive system—rectum cancer	0.000733	0.00146	CbGeAlD
Bosutinib—MAP4K1—lymph node—rectum cancer	0.000732	0.00145	CbGeAlD
Bosutinib—BTK—lymph node—rectum cancer	0.000729	0.00145	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—rectum cancer	0.000728	0.00145	CbGeAlD
Bosutinib—STK10—female reproductive system—rectum cancer	0.000726	0.00144	CbGeAlD
Bosutinib—TAOK3—female reproductive system—rectum cancer	0.000723	0.00144	CbGeAlD
Bosutinib—TNK2—lymph node—rectum cancer	0.000718	0.00143	CbGeAlD
Bosutinib—MAP3K3—vagina—rectum cancer	0.000718	0.00143	CbGeAlD
Bosutinib—MAP4K5—vagina—rectum cancer	0.000718	0.00143	CbGeAlD
Bosutinib—MAP4K2—lymph node—rectum cancer	0.000708	0.00141	CbGeAlD
Bosutinib—SRC—female reproductive system—rectum cancer	0.000705	0.0014	CbGeAlD
Bosutinib—PDGFRB—renal system—rectum cancer	0.000701	0.00139	CbGeAlD
Bosutinib—STK3—lymph node—rectum cancer	0.000699	0.00139	CbGeAlD
Bosutinib—PDGFRB—urethra—rectum cancer	0.000689	0.00137	CbGeAlD
Bosutinib—BMPR2—lymph node—rectum cancer	0.00067	0.00133	CbGeAlD
Bosutinib—STK36—lymph node—rectum cancer	0.000664	0.00132	CbGeAlD
Bosutinib—EPHB3—lymph node—rectum cancer	0.000664	0.00132	CbGeAlD
Bosutinib—YES1—vagina—rectum cancer	0.000663	0.00132	CbGeAlD
Bosutinib—STK10—vagina—rectum cancer	0.000657	0.0013	CbGeAlD
Bosutinib—MERTK—lymph node—rectum cancer	0.000657	0.0013	CbGeAlD
Bosutinib—PDGFRB—mammalian vulva—rectum cancer	0.000656	0.0013	CbGeAlD
Bosutinib—TAOK3—vagina—rectum cancer	0.000654	0.0013	CbGeAlD
Bosutinib—ABL1—smooth muscle tissue—rectum cancer	0.000649	0.00129	CbGeAlD
Bosutinib—MAP2K5—female reproductive system—rectum cancer	0.000649	0.00129	CbGeAlD
Bosutinib—MAP4K4—lymph node—rectum cancer	0.000645	0.00128	CbGeAlD
Bosutinib—NUAK2—lymph node—rectum cancer	0.00064	0.00127	CbGeAlD
Bosutinib—BCR—lymph node—rectum cancer	0.00064	0.00127	CbGeAlD
Bosutinib—MAP3K12—lymph node—rectum cancer	0.000636	0.00126	CbGeAlD
Bosutinib—CSF1R—female reproductive system—rectum cancer	0.000633	0.00126	CbGeAlD
Bosutinib—ABL1—renal system—rectum cancer	0.000625	0.00124	CbGeAlD
Bosutinib—MAP2K1—lymph node—rectum cancer	0.000623	0.00124	CbGeAlD
Bosutinib—STK35—lymph node—rectum cancer	0.000623	0.00124	CbGeAlD
Bosutinib—CSK—lymph node—rectum cancer	0.000619	0.00123	CbGeAlD
Bosutinib—CSNK1A1—lymph node—rectum cancer	0.000615	0.00122	CbGeAlD
Bosutinib—ABL1—urethra—rectum cancer	0.000614	0.00122	CbGeAlD
Bosutinib—HCK—lymph node—rectum cancer	0.000611	0.00121	CbGeAlD
Bosutinib—CLK1—lymph node—rectum cancer	0.000611	0.00121	CbGeAlD
Bosutinib—ABL2—lymph node—rectum cancer	0.000607	0.00121	CbGeAlD
Bosutinib—CAMK2G—lymph node—rectum cancer	0.000599	0.00119	CbGeAlD
Bosutinib—BMP2K—lymph node—rectum cancer	0.000599	0.00119	CbGeAlD
Bosutinib—LRRK2—lymph node—rectum cancer	0.000594	0.00118	CbGeAlD
Bosutinib—EGFR—lymph node—rectum cancer	0.000592	0.00118	CbGeAlD
Bosutinib—MAP2K5—vagina—rectum cancer	0.000587	0.00116	CbGeAlD
Bosutinib—ABL1—mammalian vulva—rectum cancer	0.000584	0.00116	CbGeAlD
Bosutinib—PTK2B—lymph node—rectum cancer	0.000579	0.00115	CbGeAlD
Bosutinib—CSF1R—vagina—rectum cancer	0.000572	0.00114	CbGeAlD
Bosutinib—CSNK1E—lymph node—rectum cancer	0.000569	0.00113	CbGeAlD
Bosutinib—PDGFRB—female reproductive system—rectum cancer	0.000561	0.00111	CbGeAlD
Bosutinib—SIK1—lymph node—rectum cancer	0.000561	0.00111	CbGeAlD
Bosutinib—IRAK4—lymph node—rectum cancer	0.000561	0.00111	CbGeAlD
Bosutinib—EPHA4—lymph node—rectum cancer	0.000555	0.0011	CbGeAlD
Bosutinib—ERBB3—lymph node—rectum cancer	0.000549	0.00109	CbGeAlD
Bosutinib—MAP2K2—lymph node—rectum cancer	0.000548	0.00109	CbGeAlD
Bosutinib—ULK3—lymph node—rectum cancer	0.000548	0.00109	CbGeAlD
Bosutinib—MAP3K2—lymph node—rectum cancer	0.000544	0.00108	CbGeAlD
Bosutinib—MAP3K7—lymph node—rectum cancer	0.000539	0.00107	CbGeAlD
Bosutinib—TBK1—lymph node—rectum cancer	0.000533	0.00106	CbGeAlD
Bosutinib—PTK2—lymph node—rectum cancer	0.000533	0.00106	CbGeAlD
Bosutinib—IRAK1—lymph node—rectum cancer	0.000523	0.00104	CbGeAlD
Bosutinib—RPS6KB1—lymph node—rectum cancer	0.000513	0.00102	CbGeAlD
Bosutinib—LCK—lymph node—rectum cancer	0.00051	0.00101	CbGeAlD
Bosutinib—FGR—lymph node—rectum cancer	0.00051	0.00101	CbGeAlD
Bosutinib—PDGFRB—vagina—rectum cancer	0.000508	0.00101	CbGeAlD
Bosutinib—AXL—lymph node—rectum cancer	0.000508	0.00101	CbGeAlD
Bosutinib—ABL1—female reproductive system—rectum cancer	0.0005	0.000994	CbGeAlD
Bosutinib—SLK—lymph node—rectum cancer	0.000489	0.00097	CbGeAlD
Bosutinib—EPHB4—lymph node—rectum cancer	0.000485	0.000963	CbGeAlD
Bosutinib—EPHA2—lymph node—rectum cancer	0.000476	0.000945	CbGeAlD
Bosutinib—FYN—lymph node—rectum cancer	0.000475	0.000943	CbGeAlD
Bosutinib—MAP4K5—lymph node—rectum cancer	0.000464	0.000922	CbGeAlD
Bosutinib—MAP3K3—lymph node—rectum cancer	0.000464	0.000922	CbGeAlD
Bosutinib—ABL1—vagina—rectum cancer	0.000453	0.000899	CbGeAlD
Bosutinib—YES1—lymph node—rectum cancer	0.000429	0.000851	CbGeAlD
Bosutinib—STK10—lymph node—rectum cancer	0.000425	0.000844	CbGeAlD
Bosutinib—TAOK3—lymph node—rectum cancer	0.000423	0.000841	CbGeAlD
Bosutinib—SRC—lymph node—rectum cancer	0.000412	0.000819	CbGeAlD
Bosutinib—MAP2K5—lymph node—rectum cancer	0.000379	0.000753	CbGeAlD
Bosutinib—CSF1R—lymph node—rectum cancer	0.00037	0.000735	CbGeAlD
Bosutinib—PDGFRB—lymph node—rectum cancer	0.000328	0.000652	CbGeAlD
Bosutinib—ABL1—lymph node—rectum cancer	0.000293	0.000581	CbGeAlD
Bosutinib—CYP3A4—renal system—rectum cancer	0.000274	0.000545	CbGeAlD
Bosutinib—ABCB1—seminal vesicle—rectum cancer	0.000241	0.000479	CbGeAlD
Bosutinib—CYP3A4—female reproductive system—rectum cancer	0.00022	0.000437	CbGeAlD
Bosutinib—ABCB1—epithelium—rectum cancer	0.000209	0.000416	CbGeAlD
Bosutinib—ABCB1—renal system—rectum cancer	0.000194	0.000386	CbGeAlD
Bosutinib—ABCB1—urethra—rectum cancer	0.000191	0.000379	CbGeAlD
Bosutinib—ABCB1—mammalian vulva—rectum cancer	0.000182	0.000361	CbGeAlD
Bosutinib—ABCB1—female reproductive system—rectum cancer	0.000156	0.000309	CbGeAlD
Bosutinib—ABCB1—vagina—rectum cancer	0.000141	0.000279	CbGeAlD
Bosutinib—ABCB1—lymph node—rectum cancer	9.1e-05	0.000181	CbGeAlD
Bosutinib—MAP2K2—Innate Immune System—KRAS—rectum cancer	2.95e-05	5.95e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—HRAS—rectum cancer	2.95e-05	5.94e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	2.93e-05	5.91e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—NRAS—rectum cancer	2.92e-05	5.87e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—KRAS—rectum cancer	2.88e-05	5.8e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—HRAS—rectum cancer	2.88e-05	5.8e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—HRAS—rectum cancer	2.87e-05	5.78e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—KRAS—rectum cancer	2.85e-05	5.74e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—HRAS—rectum cancer	2.84e-05	5.72e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—KRAS—rectum cancer	2.82e-05	5.68e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—KRAS—rectum cancer	2.81e-05	5.66e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TP53—rectum cancer	2.81e-05	5.66e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—KRAS—rectum cancer	2.81e-05	5.65e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—HRAS—rectum cancer	2.8e-05	5.64e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—KRAS—rectum cancer	2.79e-05	5.62e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—NRAS—rectum cancer	2.79e-05	5.62e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TP53—rectum cancer	2.78e-05	5.61e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—KRAS—rectum cancer	2.78e-05	5.59e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TP53—rectum cancer	2.77e-05	5.58e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—KRAS—rectum cancer	2.77e-05	5.57e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—KRAS—rectum cancer	2.76e-05	5.56e-05	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—HRAS—rectum cancer	2.76e-05	5.56e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—HRAS—rectum cancer	2.76e-05	5.55e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TP53—rectum cancer	2.74e-05	5.52e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—KRAS—rectum cancer	2.74e-05	5.52e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—KRAS—rectum cancer	2.73e-05	5.5e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—KRAS—rectum cancer	2.72e-05	5.47e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—HRAS—rectum cancer	2.72e-05	5.47e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—KRAS—rectum cancer	2.71e-05	5.46e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—HRAS—rectum cancer	2.7e-05	5.44e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—NRAS—rectum cancer	2.69e-05	5.42e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—NRAS—rectum cancer	2.69e-05	5.42e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—NRAS—rectum cancer	2.69e-05	5.41e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—KRAS—rectum cancer	2.69e-05	5.41e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—HRAS—rectum cancer	2.69e-05	5.41e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—NRAS—rectum cancer	2.68e-05	5.39e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—HRAS—rectum cancer	2.68e-05	5.39e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—HRAS—rectum cancer	2.67e-05	5.38e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—KRAS—rectum cancer	2.67e-05	5.37e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—HRAS—rectum cancer	2.66e-05	5.36e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—HRAS—rectum cancer	2.66e-05	5.36e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—HRAS—rectum cancer	2.65e-05	5.34e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—NRAS—rectum cancer	2.64e-05	5.32e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—KRAS—rectum cancer	2.64e-05	5.31e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—KRAS—rectum cancer	2.64e-05	5.31e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—KRAS—rectum cancer	2.63e-05	5.3e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—HRAS—rectum cancer	2.62e-05	5.28e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	2.61e-05	5.25e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—NRAS—rectum cancer	2.6e-05	5.23e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—HRAS—rectum cancer	2.59e-05	5.21e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—NRAS—rectum cancer	2.58e-05	5.2e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—HRAS—rectum cancer	2.57e-05	5.18e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—KRAS—rectum cancer	2.57e-05	5.17e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—NRAS—rectum cancer	2.56e-05	5.16e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—KRAS—rectum cancer	2.55e-05	5.13e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—HRAS—rectum cancer	2.51e-05	5.07e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—KRAS—rectum cancer	2.51e-05	5.06e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—HRAS—rectum cancer	2.51e-05	5.06e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—NRAS—rectum cancer	2.47e-05	4.98e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—HRAS—rectum cancer	2.45e-05	4.93e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—NRAS—rectum cancer	2.43e-05	4.89e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—HRAS—rectum cancer	2.42e-05	4.88e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—KRAS—rectum cancer	2.4e-05	4.83e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—HRAS—rectum cancer	2.4e-05	4.83e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TP53—rectum cancer	2.39e-05	4.81e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—HRAS—rectum cancer	2.39e-05	4.81e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—HRAS—rectum cancer	2.39e-05	4.8e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—NRAS—rectum cancer	2.38e-05	4.79e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—HRAS—rectum cancer	2.37e-05	4.78e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—HRAS—rectum cancer	2.36e-05	4.75e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—HRAS—rectum cancer	2.35e-05	4.74e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—HRAS—rectum cancer	2.35e-05	4.73e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TP53—rectum cancer	2.34e-05	4.72e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TP53—rectum cancer	2.34e-05	4.72e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—HRAS—rectum cancer	2.33e-05	4.69e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—HRAS—rectum cancer	2.32e-05	4.67e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—KRAS—rectum cancer	2.32e-05	4.67e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—KRAS—rectum cancer	2.32e-05	4.67e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—KRAS—rectum cancer	2.31e-05	4.66e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—HRAS—rectum cancer	2.31e-05	4.65e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—KRAS—rectum cancer	2.3e-05	4.64e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—HRAS—rectum cancer	2.3e-05	4.64e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—NRAS—rectum cancer	2.29e-05	4.61e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—NRAS—rectum cancer	2.28e-05	4.6e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—HRAS—rectum cancer	2.28e-05	4.6e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—rectum cancer	2.28e-05	4.6e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—KRAS—rectum cancer	2.27e-05	4.58e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—HRAS—rectum cancer	2.27e-05	4.57e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—rectum cancer	2.26e-05	4.56e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—HRAS—rectum cancer	2.24e-05	4.51e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—HRAS—rectum cancer	2.24e-05	4.51e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—HRAS—rectum cancer	2.23e-05	4.5e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—KRAS—rectum cancer	2.23e-05	4.5e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—KRAS—rectum cancer	2.22e-05	4.47e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—KRAS—rectum cancer	2.2e-05	4.44e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—NRAS—rectum cancer	2.19e-05	4.4e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—HRAS—rectum cancer	2.18e-05	4.4e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—HRAS—rectum cancer	2.16e-05	4.36e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—NRAS—rectum cancer	2.14e-05	4.31e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HRAS—rectum cancer	2.13e-05	4.3e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—KRAS—rectum cancer	2.13e-05	4.29e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—NRAS—rectum cancer	2.11e-05	4.25e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—KRAS—rectum cancer	2.09e-05	4.21e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—KRAS—rectum cancer	2.05e-05	4.12e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—NRAS—rectum cancer	2.05e-05	4.12e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—HRAS—rectum cancer	2.04e-05	4.11e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NRAS—rectum cancer	2.03e-05	4.09e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—rectum cancer	2.02e-05	4.07e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—NRAS—rectum cancer	2e-05	4.02e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—HRAS—rectum cancer	1.97e-05	3.97e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—HRAS—rectum cancer	1.97e-05	3.97e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—KRAS—rectum cancer	1.97e-05	3.96e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—KRAS—rectum cancer	1.97e-05	3.96e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HRAS—rectum cancer	1.97e-05	3.96e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HRAS—rectum cancer	1.96e-05	3.94e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NRAS—rectum cancer	1.96e-05	3.94e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NRAS—rectum cancer	1.96e-05	3.94e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—NRAS—rectum cancer	1.95e-05	3.93e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—HRAS—rectum cancer	1.93e-05	3.89e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—NRAS—rectum cancer	1.91e-05	3.85e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—NRAS—rectum cancer	1.9e-05	3.83e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HRAS—rectum cancer	1.9e-05	3.83e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—rectum cancer	1.89e-05	3.81e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HRAS—rectum cancer	1.89e-05	3.8e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NRAS—rectum cancer	1.89e-05	3.8e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—KRAS—rectum cancer	1.88e-05	3.79e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—NRAS—rectum cancer	1.88e-05	3.79e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—HRAS—rectum cancer	1.87e-05	3.77e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NRAS—rectum cancer	1.87e-05	3.77e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NRAS—rectum cancer	1.84e-05	3.72e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—KRAS—rectum cancer	1.84e-05	3.71e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—KRAS—rectum cancer	1.81e-05	3.65e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HRAS—rectum cancer	1.81e-05	3.65e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NRAS—rectum cancer	1.8e-05	3.63e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—NRAS—rectum cancer	1.78e-05	3.58e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HRAS—rectum cancer	1.78e-05	3.58e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—KRAS—rectum cancer	1.76e-05	3.55e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KRAS—rectum cancer	1.75e-05	3.52e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HRAS—rectum cancer	1.74e-05	3.5e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NRAS—rectum cancer	1.74e-05	3.5e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NRAS—rectum cancer	1.73e-05	3.48e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KRAS—rectum cancer	1.72e-05	3.46e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KRAS—rectum cancer	1.68e-05	3.39e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KRAS—rectum cancer	1.68e-05	3.39e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NRAS—rectum cancer	1.68e-05	3.38e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KRAS—rectum cancer	1.68e-05	3.38e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HRAS—rectum cancer	1.67e-05	3.37e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HRAS—rectum cancer	1.67e-05	3.37e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NRAS—rectum cancer	1.66e-05	3.33e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—KRAS—rectum cancer	1.64e-05	3.31e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—rectum cancer	1.64e-05	3.3e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KRAS—rectum cancer	1.64e-05	3.29e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NRAS—rectum cancer	1.62e-05	3.27e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KRAS—rectum cancer	1.62e-05	3.27e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—KRAS—rectum cancer	1.62e-05	3.26e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—rectum cancer	1.61e-05	3.25e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KRAS—rectum cancer	1.61e-05	3.24e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—rectum cancer	1.6e-05	3.22e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—rectum cancer	1.59e-05	3.2e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NRAS—rectum cancer	1.57e-05	3.16e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—rectum cancer	1.56e-05	3.15e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—NRAS—rectum cancer	1.56e-05	3.15e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—rectum cancer	1.55e-05	3.13e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—rectum cancer	1.55e-05	3.12e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—rectum cancer	1.54e-05	3.11e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—rectum cancer	1.53e-05	3.08e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NRAS—rectum cancer	1.5e-05	3.02e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—rectum cancer	1.5e-05	3.01e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—rectum cancer	1.5e-05	3.01e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—rectum cancer	1.5e-05	3.01e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—rectum cancer	1.49e-05	3.01e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—rectum cancer	1.49e-05	2.99e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—rectum cancer	1.49e-05	2.99e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—rectum cancer	1.48e-05	2.98e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—rectum cancer	1.46e-05	2.94e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TYMS—rectum cancer	1.46e-05	2.94e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—rectum cancer	1.44e-05	2.91e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—rectum cancer	1.44e-05	2.91e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—rectum cancer	1.44e-05	2.91e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—rectum cancer	1.43e-05	2.88e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—rectum cancer	1.43e-05	2.88e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—rectum cancer	1.43e-05	2.87e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—rectum cancer	1.42e-05	2.87e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—rectum cancer	1.4e-05	2.81e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—rectum cancer	1.4e-05	2.81e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—rectum cancer	1.39e-05	2.8e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—rectum cancer	1.39e-05	2.79e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—rectum cancer	1.38e-05	2.78e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—rectum cancer	1.37e-05	2.77e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—rectum cancer	1.37e-05	2.75e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—rectum cancer	1.35e-05	2.72e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—rectum cancer	1.35e-05	2.72e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—rectum cancer	1.35e-05	2.71e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—rectum cancer	1.32e-05	2.65e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—rectum cancer	1.3e-05	2.62e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—rectum cancer	1.29e-05	2.6e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—rectum cancer	1.29e-05	2.6e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—rectum cancer	1.28e-05	2.59e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—rectum cancer	1.28e-05	2.58e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—rectum cancer	1.27e-05	2.56e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—rectum cancer	1.27e-05	2.56e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—rectum cancer	1.27e-05	2.55e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—rectum cancer	1.26e-05	2.54e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—rectum cancer	1.26e-05	2.54e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—rectum cancer	1.24e-05	2.5e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—rectum cancer	1.23e-05	2.49e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—rectum cancer	1.23e-05	2.47e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—rectum cancer	1.22e-05	2.45e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—rectum cancer	1.21e-05	2.44e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—rectum cancer	1.21e-05	2.43e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—rectum cancer	1.2e-05	2.42e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—rectum cancer	1.19e-05	2.4e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—rectum cancer	1.19e-05	2.39e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—rectum cancer	1.15e-05	2.31e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—rectum cancer	1.14e-05	2.31e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—rectum cancer	1.13e-05	2.28e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—rectum cancer	1.11e-05	2.24e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—rectum cancer	1.1e-05	2.22e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—rectum cancer	1.1e-05	2.21e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—rectum cancer	1.09e-05	2.19e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—rectum cancer	1.08e-05	2.18e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—rectum cancer	1.06e-05	2.14e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—rectum cancer	1.06e-05	2.13e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—rectum cancer	1.05e-05	2.11e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—rectum cancer	1.05e-05	2.11e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—rectum cancer	1.04e-05	2.1e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—rectum cancer	1.01e-05	2.04e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—rectum cancer	1.01e-05	2.04e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—rectum cancer	9.88e-06	1.99e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—rectum cancer	9.64e-06	1.94e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—rectum cancer	9.45e-06	1.9e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—rectum cancer	9.44e-06	1.9e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—rectum cancer	9.36e-06	1.88e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—rectum cancer	9.3e-06	1.87e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—rectum cancer	9.25e-06	1.86e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—rectum cancer	9.22e-06	1.86e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—rectum cancer	9.04e-06	1.82e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—rectum cancer	9.03e-06	1.82e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—rectum cancer	9e-06	1.81e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—rectum cancer	8.96e-06	1.8e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—rectum cancer	8.89e-06	1.79e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—rectum cancer	8.84e-06	1.78e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—rectum cancer	8.71e-06	1.75e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—rectum cancer	8.03e-06	1.62e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—rectum cancer	7.74e-06	1.56e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—rectum cancer	7.71e-06	1.55e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—rectum cancer	7.68e-06	1.55e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—rectum cancer	7.4e-06	1.49e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—rectum cancer	6.85e-06	1.38e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—rectum cancer	6.55e-06	1.32e-05	CbGpPWpGaD
